Fig 1.
Design of the EpleCsAT: Safety trial.
Sequential inclusion was performed: 14 patients during step 1; then 17 new patients during step 2.
Fig 2.
Eplerenone induced mild hyperkalemia.
(A) Kalemia increased from day 2 (D2) and became stable during the treatment period. (B) Systolic blood pressure (SBP), (C) body weight, and (D) serum bicarbonate did not change during the treatment period. Data are represented as their median and range (whiskers). * p <0.05 vs. D0.
Table 1.
Characteristics of included patients.
Table 2.
Candidate parameters for predicting the risk of mild hyperkalemia.
Fig 3.
Risk factors for developing mild hyperkalemia under treatment.
Receiver-operating characteristic (ROC) curves for (A) serum potassium and (B) serum bicarbonate at baseline.